Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181162 | 0.90 | CXCR2 (0.36) | NR3C1CXCR2SCN2A | |
| SCHEMBL4179120 | 0.88 | SCN2A (0.33) | CXCR2SCN2AMAPK13RAF1MAPK12 | |
| SCHEMBL4178043 | 0.84 | PTGS2 (0.38) | NR3C1 | |
| SCHEMBL4185707 | 0.83 | NR3C1 (0.38) | NR3C1 | |
| SCHEMBL4174950 | 0.79 | CSF1R (0.36) | NR3C1 | |
| SCHEMBL4173252 | 0.72 | PTGS2 (0.37) | — | |
| SCHEMBL4174808 | 0.71 | HPGDS (0.31) | — | |
| SCHEMBL4173820 | 0.71 | AGTR1 (0.31) | — | |
| SCHEMBL4181577 | 0.70 | NOS1 (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL4174291 | 0.68 | CSF1R (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | NR3C1 3725/4885CXCR2 813/4885SCN2A 4565/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | NR3C1 3725/4885CXCR2 813/4885SCN2A 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.